Assessing erythropoiesis and the effect of erythropoietin therapy in renal disease by reticulocyte counting.
Renal disease is characterized by failure of erythropoietin (Epo) production and low bone marrow sensitivity to Epo. The reticulocyte count is the best laboratory marker of erythropoiesis available, but reticulocytes have not been extensively studied in renal disease. Cluster analysis suggests that in non-haemodialysed renal patients the anaemia is associated with uraemia while the reticulocyte number and immature subclasses are correlated with the ineffective erythropoietic component of the anaemia. This emphasizes the importance of treating the renal disease in patients with the anaemia of end-stage renal failure. Human recombinant Epo therapy has been demonstrated to be effective in correcting anaemia in most cases of chronic renal insufficiency. In renal patients the reticulocyte count should only be monitored by automated methods to assure reliability at low counts.
Pradella
M
M
Ospedale di Castelfranco Veneto, Castelfranco(TV), Italy.
Cavill
I
I
d'Onofrio
G
G
D000740:Anemia / Q000097:blood / Q000188:drug therapy; D016000:Cluster Analysis; D004920:Erythropoiesis / Q000187:drug effects* / Q000502:physiology; D004921:Erythropoietin / Q000627:therapeutic use*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000188:drug therapy*; D011994:Recombinant Proteins; D017701:Reticulocyte Count / Q000187:drug effects
D011994:Recombinant Proteins; D004921:Erythropoietin